CF Lung Function Improved With Proteostasis’ Triple Combo, Trial Shows
A triple combination that includes dirocaftor (PTI-808) led to lung function improvements in CF patients with the F508del mutation, a Phase 2 trial shows. Read more here.
What do you think about this study and its findings?
Sorry, there were no replies found.
Log in to reply.